Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


28.11.2022

2 Am J Hematol
1 Ann Oncol
3 Blood
2 BMC Cancer
6 Br J Haematol
2 Int J Hematol
1 Leuk Lymphoma
1 Leuk Res
2 Leukemia
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. RADICH J
    Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!
    Am J Hematol. 2022 Nov 24. doi: 10.1002/ajh.26790.
    PubMed        

  2. LEVI S, Bronstein Y, Goldschmidt N, Morabito F, et al
    Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26779.
    PubMed        


    Ann Oncol

  3. BAZINET A, Kantarjian HM
    Moving towards individualized target-based therapies in acute myeloid leukemia.
    Ann Oncol. 2022 Nov 21:S0923-7534(22)04734-2. doi: 10.1016/j.annonc.2022.
    PubMed         Abstract available


    Blood

  4. GHOBADI A, Slade M, Kantarjian H, Alvarenga J, et al
    The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
    Blood. 2022;140:2101-2112.
    PubMed         Abstract available

  5. THIJSSEN R, Tian L, Anderson MA, Flensburg C, et al
    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
    Blood. 2022;140:2127-2141.
    PubMed         Abstract available

  6. THOMALLA D, Beckmann L, Grimm C, Oliverio M, et al
    Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
    Blood. 2022;140:2113-2126.
    PubMed         Abstract available


    BMC Cancer

  7. CANTONI N, Sommavilla R, Seitz P, Kulenkampff E, et al
    A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
    BMC Cancer. 2022;22:1192.
    PubMed         Abstract available

  8. LI XY, Zhan LP, Liu DD, Han XW, et al
    Impact of posttransplant cyclophosphamide on the outcome of patients undergoing unrelated single-unit umbilical cord blood transplantation for pediatric acute leukemia.
    BMC Cancer. 2022;22:1190.
    PubMed         Abstract available


    Br J Haematol

  9. COPLAND M
    Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
    Br J Haematol. 2022;199:665-678.
    PubMed         Abstract available

  10. MUNIR T, Emmerson J, Hockaday A, Oughton JB, et al
    Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
    Br J Haematol. 2022;199:707-719.
    PubMed         Abstract available

  11. ATKINS O, Mirvis E, Maynard S, Katsomitrou V, et al
    Acute myeloid leukaemia presenting with Sweet syndrome.
    Br J Haematol. 2022;199:637.
    PubMed        

  12. WEI S, Gu R, Song Y, Yan Z, et al
    Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients.
    Br J Haematol. 2022;199:772-776.
    PubMed        

  13. CANALI A, Rieu JB
    Morphological characterization of acute myeloid leukaemia with t(11;17)(q23;q21)/ZBTB16::RARA fusion.
    Br J Haematol. 2022;199:638.
    PubMed        

  14. LI H, Xiang X, Ding H, Yu J, et al
    Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
    Br J Haematol. 2022;199:768-771.
    PubMed        


    Int J Hematol

  15. KARADAS N, Goktepe SSO, Bas I, Ece D, et al
    Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment.
    Int J Hematol. 2022 Nov 19. doi: 10.1007/s12185-022-03497.
    PubMed         Abstract available

  16. IWAI T, Nishida M, Sugita J, Yasumoto A, et al
    Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin.
    Int J Hematol. 2022;116:973-975.
    PubMed        


    Leuk Lymphoma

  17. MULLIGAN SP, Opat S, Cheah CY, Kuss B, et al
    Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
    Leuk Lymphoma. 2022 Nov 24:1-7. doi: 10.1080/10428194.2022.2148220.
    PubMed         Abstract available


    Leuk Res

  18. ABEDIN SM, Badar T, Gauger K, Michaelis LC, et al
    Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2022;123:106984.
    PubMed        


    Leukemia

  19. STEINHAUSER S, Silva P, Lenk L, Beder T, et al
    Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).
    Leukemia. 2022 Nov 21. doi: 10.1038/s41375-022-01751.
    PubMed         Abstract available

  20. LING VY, Straube J, Godfrey W, Haldar R, et al
    Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
    Leukemia. 2022 Nov 18. doi: 10.1038/s41375-022-01755.
    PubMed         Abstract available


    PLoS One

  21. CHEN Y, Wu T, Yang C, Lu M, et al
    A pyridinesulfonamide derivative FD268 suppresses cell proliferation and induces apoptosis via inhibiting PI3K pathway in acute myeloid leukemia.
    PLoS One. 2022;17:e0277893.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: